Drugs / PEMRAMETOSTAT
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02783300 | Aug 2016 → Aug 2023 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03614728 | Oct 2018 → Jan 2022 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04676516 | Jun 2021 → Aug 2022 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEMRAMETOSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4466233 ↗ |
| Known as | EPZ-015938 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4466233 ↗ |
| Known as | GSK-3326595A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4466233 ↗ |
| Known as | GSK3326595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04676516 ↗ |
| Action | Inhibit | “GSK3326595 is a first-generation protein arginine methyltransferase 5 inhibitor.” PMID 40935292 ↗ Sep 2025 |
| Modality | Small molecule | “first-in-class small molecule PRMT5 inhibitor” NCT04676516 ↗ |
| Route | Oral | “oral GSK3326595 monotherapy” PMID 40935292 ↗ Sep 2025 |
| Target | PRMT5 | “a PRMT5 inhibitor” PMID 40935292 ↗ Sep 2025 |